The Fort Worth Press - Bayer shares hit 20-yr low as problems pile up

USD -
AED 3.673005
AFN 68.386442
ALL 93.021933
AMD 389.349314
ANG 1.803734
AOA 913.000031
ARS 1002.721397
AUD 1.53358
AWG 1.8
AZN 1.702057
BAM 1.854577
BBD 2.020785
BDT 119.602116
BGN 1.858799
BHD 0.376916
BIF 2956.030306
BMD 1
BND 1.344124
BOB 6.930721
BRL 5.790848
BSD 1.000863
BTN 84.433613
BWP 13.672612
BYN 3.275301
BYR 19600
BZD 2.017372
CAD 1.39639
CDF 2864.999911
CHF 0.88374
CLF 0.035265
CLP 973.069559
CNY 7.241401
CNH 7.24719
COP 4396.59
CRC 508.251983
CUC 1
CUP 26.5
CVE 104.558213
CZK 24.0877
DJF 178.22092
DKK 7.087555
DOP 60.364405
DZD 133.750861
EGP 49.678296
ERN 15
ETB 124.782215
EUR 0.950275
FJD 2.269701
FKP 0.789317
GBP 0.791103
GEL 2.740301
GGP 0.789317
GHS 15.887842
GIP 0.789317
GMD 71.000247
GNF 8627.008472
GTQ 7.726299
GYD 209.391416
HKD 7.782965
HNL 25.291226
HRK 7.133259
HTG 131.472895
HUF 390.756993
IDR 15903.25
ILS 3.732285
IMP 0.789317
INR 84.493503
IQD 1311.043259
IRR 42092.505939
ISK 138.290123
JEP 0.789317
JMD 158.639851
JOD 0.709302
JPY 154.656495
KES 129.249619
KGS 86.506766
KHR 4038.536303
KMF 467.499881
KPW 899.999621
KRW 1398.125025
KWD 0.30759
KYD 0.834076
KZT 497.17423
LAK 21976.521459
LBP 89633.50686
LKR 291.187013
LRD 181.150969
LSL 18.152914
LTL 2.95274
LVL 0.60489
LYD 4.883414
MAD 9.998293
MDL 18.214834
MGA 4685.233124
MKD 58.48862
MMK 3247.960992
MNT 3397.999946
MOP 8.024142
MRU 39.785889
MUR 46.412517
MVR 15.460006
MWK 1735.461174
MXN 20.325297
MYR 4.464971
MZN 63.950307
NAD 18.152914
NGN 1680.590024
NIO 36.829479
NOK 11.03348
NPR 135.09167
NZD 1.703345
OMR 0.385001
PAB 1.000778
PEN 3.7981
PGK 4.029035
PHP 59.039501
PKR 278.226704
PLN 4.126669
PYG 7838.117183
QAR 3.649699
RON 4.729799
RSD 111.205995
RUB 101.000437
RWF 1380.157217
SAR 3.754257
SBD 8.355531
SCR 13.619994
SDG 601.497088
SEK 11.030315
SGD 1.343699
SHP 0.789317
SLE 22.575045
SLL 20969.504736
SOS 571.975839
SRD 35.43028
STD 20697.981008
SVC 8.757041
SYP 2512.529858
SZL 18.142596
THB 34.647019
TJS 10.658746
TMT 3.5
TND 3.159078
TOP 2.342102
TRY 34.465475
TTD 6.776157
TWD 32.567494
TZS 2652.359028
UAH 41.269214
UGX 3693.413492
UYU 42.784805
UZS 12854.406494
VES 46.433371
VND 25422.5
VUV 118.722009
WST 2.791591
XAF 622.001915
XAG 0.032192
XAU 0.000375
XCD 2.70255
XDR 0.761528
XOF 622.001915
XPF 113.087675
YER 249.924998
ZAR 18.116198
ZMK 9001.198706
ZMW 27.697968
ZWL 321.999592
  • RYCEF

    -0.0800

    6.61

    -1.21%

  • RBGPF

    -0.5000

    59.69

    -0.84%

  • CMSC

    -0.0450

    24.52

    -0.18%

  • BTI

    -0.1400

    36.94

    -0.38%

  • RIO

    -0.0100

    62.38

    -0.02%

  • SCS

    -0.0200

    13.07

    -0.15%

  • GSK

    0.0350

    33.385

    +0.1%

  • CMSD

    -0.0836

    24.26

    -0.34%

  • VOD

    -0.0150

    8.925

    -0.17%

  • AZN

    0.6420

    63.842

    +1.01%

  • BCE

    -0.1800

    26.82

    -0.67%

  • RELX

    0.2700

    45.38

    +0.59%

  • BP

    0.2200

    29.3

    +0.75%

  • BCC

    -0.7700

    137.41

    -0.56%

  • JRI

    -0.0300

    13.23

    -0.23%

  • NGG

    -0.1600

    63.11

    -0.25%

Bayer shares hit 20-yr low as problems pile up
Bayer shares hit 20-yr low as problems pile up / Photo: © AFP

Bayer shares hit 20-yr low as problems pile up

Bayer's shares plunged to a 20-year low Tuesday after the German chemicals giant cut its earnings outlook and posted a worse-than-expected loss on woes related to its troubled agrochemicals division.

Text size:

The group vowed to press ahead with its cost-cutting efforts after reporting a loss of 4.18 billion euros ($4.45 billion) in the three months to the end of September, much worse than analysts' forecasts.

It was weighed down by bad news from its agrochemicals division, including a heavy drop in sales of its glyphosate-based weedkillers, at the centre of long-running legal fights in the United States over claims they cause cancer.

Earnings at the agricultural unit were also hit by a hefty writedown on assets.

Bayer, which also makes pharmaceuticals and consumer health products, saw its shares plunge more than 11 percent on the Frankfurt Stock Exchange after reporting its second quarterly loss in a row.

It is a fresh headache for CEO Bill Anderson, who was hired last year to steer the troubled group in a new direction, and has launched a major restructuring drive while resisting calls from activist investors for a break-up of the group.

They also reflect a bleak picture for Germany's traditional manufacturers generally, who are struggling with challenges ranging from high costs to weak demand, as Europe's top economy heads for a second straight year of contraction.

The problems for Bayer, the maker of Aspirin, looked set to continue in 2025 with chief financial officer Wolfgang Nickl warning of a "muted outlook" next year, "with likely declining earnings".

"We plan to accelerate our cost and efficiency measures," he said.

- 'No quick fix' -

After Tuesday's results, the Leverkusen-based group lowered its 2024 outlook for EBITDA -- or operating earnings, a key measure of profitability -- to between 10.4 billion and 10.7 billion euros from a previous forecast of between 10.7 billion and 11.3 billion euros.

It also cut the outlook for profit margins in the agrochemicals division.

Anderson is aiming to make savings of two billion euros a year from 2026, in particular by reducing management positions.

The group has already cut some 5,500 jobs since the start of the year, including 3,200 in the first half, according to the CEO.

It is also hoping for progress in resolving the massive litigation issues linked to the Roundup weedkiller, a problem it inherited in the 2018 takeover of US firm Monsanto.

The group has faced a wave of lawsuits in the United States over claims Roundup, which contains the active ingredient glyphosate, causes cancer. Bayer denies the claim but has spent billions of euros on legal costs.

It hopes the US Supreme Court will take up the cases related to Roundup in order to clarify the legal situation.

Bayer is considering which case to bring to the court and, if it does, would expect a decision in the 2025-26 term, said Anderson.

But he cautioned: "This is a long road, with no quick fix."

Sales overall edged up slightly in the quarter to 9.97 billion euros.

Away from the agrochemicals unit, the picture was brighter, with higher sales in the pharmaceuticals division due to strong sales of some blockbuster drugs.

The consumer health unit also reported higher earnings and sales.

L.Holland--TFWP